Schizophrenia & Other Psychotic Disorders
Out Of The Pipeline
Dexmedetomidine sublingual film for agitation
Approved by the FDA on April 5, 2022, dexmedetomidine sublingual film (Igalmi, manufactured and distributed by BioXcel Therapeutics, Inc., New...
Cases That Test Your Skills
Should clozapine be discontinued in a patient receiving chemotherapy?
Mr. A is diagnosed with leukemia. He has schizophrenia and has long been stable on clozapine. Can this medication be continued, or is the risk of...
Conference Coverage
Telepsychiatry helped maintain standard of schizophrenia care during COVID
For patients with schizophrenia treated with LAIs, the frequency of telepsychiatry visits increased in 46% of the clinics during the pandemic.
Conference Coverage
Antipsychotic safe, effective for resistant depression in phase 3 trial
Previous research has shown almost half of patients with MDD do not experience satisfactory results from their current treatment regimen.
From the Journals
Multiple mental health woes? Blame it on genetics
The results could lead to the development of treatments that address multiple psychiatric disorders at once.
From the Journals
The psychopathic brain: New insight
“In addition to social environmental influences ... there can be differences in biology, in this case, the size of brain structures, between...
From the Journals
Neuropsychiatric risks of COVID-19: New data
“Neuropsychological sequelae need to be considered after all severe respiratory infections, rather than only following severe COVID-19,” said Dr....
From the Journals
Clozapine and cancer risk in schizophrenia patients: New data
The clozapine-related risk increase was specific to hematological malignancies only.
From the Journals
New data support electroconvulsive therapy for severe depression
In today’s practice, ECT leads to fewer cognitive side effects than previous treatments.
From the Journals
Do psychotropic meds raise or lower COVID risk in psych patients?
The researchers analyzed data from adults who were continuously hospitalized with serious mental illness in 2020.
From the Journals
Higher ‘chemical restraint’ rates in Black psych patients in the ED
Black patients presenting with a psychiatric disorder were significantly more likely to receive chemical sedation than White patients presenting...